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Dkk-3 is a member of the dickkopf protein family of secreted inhibitors of the Wnt
pathway, which has been shown to enhance angiogenesis. The mechanism underlying
this effect is currently unknown. Here, we used cultured HUVECs to study the involvement
of the TGF-β and VEGF on the angiogenic effect of Dkk-3. Addition of hrDkk-3 peptide
(1 or 10 ng/ml) to HUVECs for 6 or 12 h enhanced the intracellular and extracellular
VEGF protein levels, as assessed by RTPCR, immunoblotting, immunocytochemistry
and ELISA. The increase in the extracellular VEGF levels was associated to the VEGFR2
activation. Pharmacological blockade of VEGFR2 abrogated Dkk-3-induced endothelial
cell tubes formation, indicating that VEGF is a molecular player of the angiogenic effects
of Dkk-3. Moreover, Dkk-3 enhanced Smad1/5/8 phosphorylation and recruited Smad4
to the VEGF gene promoter, suggesting that Dkk-3 activated ALK1 receptor leading to
a transcriptional activation of VEGF. This mechanism was instrumental to the increased
VEGF expression and endothelial cell tubes formation mediated by Dkk-3, because both
effects were abolished by siRNA-mediated ALK1 knockdown. In summary, we have
found that Dkk-3 activates ALK1 to stimulate VEGF production and induce angiogenesis
in HUVECs.
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INTRODUCTION
Dickkopf-3 (Dkk-3) is a divergent member of the Dkk protein family of secreted inhibitors of the
Wnt pathway, which exerts pleiotropic functions in different biological contexts (Niehrs, 2006).
Unlike Dkk-1 and other Dkk family members, a precise role for Dkk-3 in the modulation of the
Wnt pathway has not been identified to date (Krupnik et al., 1999; Wu et al., 2000; Mao B. et al.,
2001; Mao J. et al., 2001; Mao et al., 2002; Diep et al., 2004; Veeck and Dahl, 2012).
Of note, human Dkk-3 was proposed to function as a tumor suppressor because its expression
was shown to be down-regulated in cancer cells (Nozaki et al., 2001; Kurose et al., 2004; Lodygin
et al., 2005; Kuphal et al., 2006). Dkk-3 might also display angiogenic activity during embriogenesis
and tumor development (Untergasser et al., 2008). The molecular mechanisms underlying the
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angiogenic activity of Dkk-3 are currently unknown. Studies
carried out in tumor cell lines have shown that Dkk-3 enhanced
phosphorylation of Smad3 (Kashiwakura et al., 2008), a molecule
that lies along the signaling pathway activated by TGF-β1. The
latter has an established role in angiogenesis (Lebrin et al., 2005;
López-Novoa and Bernabeu, 2010).
TGF-β1 acts as a modulator of endothelial cell proliferation
and migration by activating two subtypes of TGF-β1 type I
receptors named ALK5 (Activin like kinase 5) and ALK1 (Activin
like kinase 5). In particular, TGF-β1 enhances endothelial cell
migration and proliferation by activating the ALK1 receptor
subtype whereas it does the opposite acting on ALK5 receptor
(Goumans et al., 2002; Lebrin et al., 2005). TGF-β can modulate
angiogenesis by regulating the expression of VEGF in vascular
endothelial cells (Seghezzi et al., 1998; Ferrara et al., 2003;
Ferrara, 2004; Ferrari et al., 2006). Of note, VEGF is under
the transcriptional control of TGFβ-/Smad signaling pathway
(Clifford et al., 2008).
The direct evidence that Dkk-3 activates the TGF-β/VEGF
pro-angiogenic pathway is still lacking.
The aim of our study was to characterize the molecular
mechanism underlying the angiogenic activity of Dkk-3 by
assessing the involvement of the TGF-β1 intracellular signaling
and testing the hypothesis that VEGF may be a transcriptional
target of Dkk-3 in HUVECs.
MATERIALS AND METHODS
Materials
hrDkk-3 peptide (R&D Systems, Minneapolis, MN,
USA); ML347 (Tocris Bioscience, Bristol, UK); Oligo:
SASI_Hs01_00113768 (Sigma Aldrich, Milan, Italy);
Recombinant Human TGF beta-1 (Millipore, Billerica, MA,
USA); ZM 323881 (Tocris Bioscience).
Endothelial Cell Cultures
Commercially available HUVECs (Lonza, Walkersville, MD,
USA, code: CC-2517, lot number: 0000323352) were used within
4 passages for in vitro experiments. These cells have been
reviewed by Quality Assurance in compliance with requirements
of Lonza’s Quality System. Cells were cultured in endothelial
growth medium-2 (EGM-2) (Lonza) supplemented with 10%
dialyzed fetal bovine serum (Life Technologies, Carlsbad, CA,
USA), at 37◦C in a humidified atmosphere with 5% CO2.
Semiconfluent HUVEC cultures (2.5 × 105 cells/well) were
stimulated with either vehicle or the human recombinant Dkk-3
Abbreviations:ALK, Activin Like Kinase; ChIP, Chromatin Immunoprecipitation;
Dkk-3, Dickkopf-3; EDTA, Ethylenediaminetetraacetic Acid; EGM-2, Endothelial
Cell Growth Medium-2; ELISA, Enzyme-Linked Immunosorbent Assay;
HUVECs, Human Umbilical Vein Endothelial Cells; hrDkk-3, human
recombinant Dkk-3; PBS, Phosphate Buffer Solution; PIPES, Piperazine-
N,N′-bis(Ethanesulfonic acid); RTPCR, Real Time Polymerase chain reaction;
SDS, Sodium dodecyl sulfate; SiRNA, Short interfering RNA; Smad, small mother
against decapentaplegic; TGF-β, Transforming Growth Factor beta; Tris-HCl,
Trisaminomethane Hydrochloride; VEGF, Vascular Endothelial Growth Factor;
VEGFR2, Vascular Endothelial Growth Factor Receptor 2; Wnt, Wingless
Integration site.
peptide (hrDkk-3, R&D Systems) at a final concentration of
either 1 or 10 ng/ml.
These concentrations were chosen based on the literature
data supporting Dkk-3 ability to induce angiogenesis in vitro
in primary endothelial colony-forming cells (Untergasser et al.,
2008).
Control plates were maintained in EGM-2 medium. The
incubation was stopped after short times (30, 60, and 90
min) and cell lysates were used for western blot analysis
of phosphoSmad1/5/8 expression. Longer times incubation
(6 and 12 h) were performed for RTPCR, western blot,
immunocytochemical analysis of VEGF expression, western blot
analysis of the phosphorylated (activated) form of the VEGFR2
receptor. The culture medium was collected for ELISA of the
VEGF extracellular levels.
Moreover, HUVECs were tested for endothelial cell tubes
formation on Matrigel following different times of incubation
(from 1 to 48 h) with hrDkk-3 (10 ng/ml). The endothelial cell
tubes formation was evaluated at the end of 18 h of incubation
with hrDkk-3 (10 ng/ml) either in presence or in the absence
of the selective VEGFR2 antagonist ZM 323881 (1 µM, Tocris
Bioscience).
In separate sets of experiments, HUVECs were subjected to
ALK1 gene silencing by using small interfering RNAs (siRNA,
Sigma Aldrich; Oligo: SASI_Hs01_00113768; Sequence: 5′-
CCCUCUACGACUUUCUGCA-3′). After 48 h of transfection,
both control and silenced HUVECs were incubated with
vehicle or hrDkk-3 (10 ng/ml) and used as follows: (i) cell
lysates collected after 1 h of incubation were used for western
blot analysis of phosphoSmad1/5/8 expression; (ii) cell lysates
collected after 12 h of incubation were used to assess VEGF
expression by Western blot and immunocytochemical analysis.
Moreover, the endothelial cell tubes formation assay was
performed in ALK1 silenced and not silenced HUVECs grown
for 18 h on Matrigel either in the presence or in the absence of
the Dkk3 peptide (10 ng/ml).
To better assess the role of ALK1 in Dkk-3 mediated VEGF
upregulation, the VEGF intracellular expression was assessed by
western blot in HUVECs following incubation with hrDkk-3
(10 ng/ml, 12 h) either in the presence or in the absence of
the selective ALK1 antagonist ML347 (0.5 or 1 µM, Tocris
Bioscience).
Finally, the phospho-Smad1,5,8 expression was evaluated
following incubation with hrDkk-3 (10 ng/ml) for 60 min either
in the presence or in the absence of neutralizing TGF-β antibody
(10 ng/ml, Sigma Aldrich, code: T0438, lot number: 077K1267).
The VEGF intracellular expression was assessed after 12 h of
incubation with hrDkk-3 in the same experimental condition.
RTPCR Analysis
Total RNA was extracted from cells using Trizol reagent (Life
Technologies), subjected to DNAse I treatment (Qiagen, Venlo,
Netherlands), and subsequently purified using RNeasy Mini
Kit (Qiagen) according to the manufacturer’s instructions. RNA
integrity was assessed by denaturing agarose gel electrophoresis
and its concentration was verified by using NanoDrop2000c UV-
Vis spectrophotometer (Thermo Scientific,Waltham,MA, USA).
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VEGF mRNA Analysis
One µg of total RNA was used for cDNA synthesis using
Superscript VILO master mix (Life Technologies) according to
manufacturer’s instructions. The following primers were used:
VEGF: forward 5′-TCTTCAAGCCATCCTGTGTG-3′; reverse
5′- CTCATCTCTCCTATGTGCTG-3′; GAPDH: forward 5′-
ACAGTCAGCCGCATCTTC-3′; reverse 5′-GCCCAATACGAC
CAAATCC-3′. RTPCR was performed using a 2× SYBR Green
PCR Master Mix (Applied Biosystems, Forster City, CA, USA)
containing the double-stranded DNA-binding fluorescent probe,
Sybr Green, and all necessary components except primers.
Quantitative PCR conditions included an initial denaturation
step of 94◦C/10 min followed by 40 cycles of 94◦C/15 s and
60◦C/15 s. Measurements were performed in triplicate in each
assay. Results were expressed as relative levels of VEGF mRNA
at 6 and 12 h compared with basal time.
ALK1 Gene Silencing Validation
HUVECs subjected to 48 h of transfection with control- or
ALK1 silencing siRNA were used for total RNA extraction
and cDNA synthesis. RTPCR was used to verify the efficiency
of gene silencing by using the following primers: ALK1:
forward 5′-ATGACCTCCCGCAACTCGA-3′; reverse 5′- TAG
AGGGAGCCGTGCTCGT-3′; β-actin: forward 5′-GCAAGA
GATGGCCACGGCTG-3′; reverse 5′-CCACAGGACTCCATG
CCCAG-3′. Measurements were performed in triplicate. Results
were expressed as relative levels of ALK1 mRNA compared with
control cells.
ChIP
ChIP assay was performed by standard procedures. Cells were
fixed with 1% formaldehyde for 10 min at room temperature
with swirling. The crosslinking reaction was stopped by adding
glycine to a final concentration of 0.125 M, and the incubation
was continued for an additional 5 min. Cells were washed
three times with cold PBS, harvested by scraping, pelleted,
and resuspended in 1 mL of lysis buffer (5 mM PIPES pH 8.0,
85 mM KCl, 0.5% NP40, 1× protease inhibitor) and nuclei
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.0,
protease inhibitor) and then sonicated on ice using a Covaris
S220 ultrasonicator. Following sonication, chromatin fragments
of 0.2–0.6 kb in length were obtained. Ten percent of the
sonicated lysate was saved and successively used to quantify
the total amount of DNA present in different samples before
immunoprecipitation (Inputs). The chromatin solution was
precleared with salmon sperm DNA/protein A-agarose 50%
gel slurry for 1 h at 4◦C and immunoprecipitated overnight at
4◦C with antibody against Smad4 (Cell Signaling Technology,
Danvers, USA) or the respective isotype matched control Ig.
After precipitation, the chromatin-antibody complexes were
collected using Protein A Sepharose beads and washed. Samples
were then eluted with 1% SDS, 100 mM NaHCO3 at room
temperature for 15 min, reverse cross-linked with NaCl 100 mM
at 65◦C overnight and treated with proteinase-K. Protein-free
DNA was extracted by phenol/chloroform/isoamyl alcohol,
precipitated with 100% ethanol, and analyzed by RTPCR
using the following specific primers for VEGF promoter:
forward GCGTGTCTCTGGACAGAGTTT and reverse
AGCCTCAGCCCTTCCACA. RTPCR was performed with
15 µl reactions Universal STBR Green (Bio Rad, Hercules, CA,
USA) on an Applied Biosystems Step-One instrument. Thermal
cycler conditions were as follows: 10 min at 95◦C, 40 cycles of
denaturation (15 s at 95◦C), and combined annealing/extension
(1 min at 60◦C). The VEGF promoter amplification was
estimated by using the following equation: % (DNA-IP/total
input)= 2∧[Ct(10% input)− 3.32)− Ct (DNA− IP)]× 100%.
Immunocytochemistry
Following incubation with hrDkk-3, cells were fixed in 4%
paraformaldehyde and incubated overnight with a rabbit
polyclonal anti-VEGF (1:300; Abcam, Cambridge, UK, code:
ab46154, lot number: GR218557-1) and then for 1 h with
a secondary biotinylated anti-rabbit antibody (1:200; Vector
Laboratories, Burlingame, CA, USA, code: BA-1000; lot number:
ZA0324). 3,3-Diaminobenzidine tetrachloride was used for
detection. The immunoreactivity was quantified by densitometric
analysis.
Western Blot Analysis
Western blot analysis were carried out by using the following
primary antibodies: rabbit polyclonal anti-phosphorylated
Smad1,5,8 (1:1000, Cell Signaling Technology, code: 9511; lot
number:14) rabbit polyclonal anti-Smad1 antibody (1:1000,
Cell Signaling Technology, code: 9743; lot number: 2) rabbit
polyclonal anti-VEGF antibody (1:1000, Abcam, code: ab46154;
lot number: GR218557-1), mouse monoclonal anti-β-actin
antibody (1:50000, Sigma Aldrich, code: A5441; lot number:
061M4808), rabbit polyclonal anti-Phospho-VEGF receptor
2 (P-VEGFR2) antibody (1:1000, Cell Signaling Technology,
code: 2478; lot number: 13) or rabbit polyclonal VEGFR2
(1:1000, Cell Signaling Technology, code: 2479; lot number:
18). After incubation with primary antibodies, filters were
washed and incubated with secondary peroxidase-coupled
antibodies anti-rabbit (1:6000, Calbiochem, Milan, Italy, code:
401393; lot number: D00051552) or anti-mouse (1:5000,
Santa Cruz Biotechnology, Dallas, TX, USA, code: sc-2005; lot
number: H0513). Immunostaining was revealed by enhanced
chemiluminescence luminosity (GE Healthcare, Milan, Italy).
VEGF ELISA
After 6 h of incubation with hrDkk-3 (1 or 10 ng/ml), the
culture medium was removed and used for the assessment of
the VEGF extracellular level. The latter was measured with
a VEGF DuoSet enzyme-linked immunosorbent assay (ELISA;
R&D Systems, code: DVE00; lot number: 330898), according to
the manufacturer’s instructions. The results were expressed as
pg/mL.
Angiogenesis Assay on Matrix Gels
HUVEC tubes formation was studied with Matrigel (BD
Biosciences, San Jose, CA, USA), as previously reported
(Scarpino et al., 2009). Briefly, growth factor-reduced Matrigel
was allowed to polymerize for 1 h at 37◦C. Cell tubes
formation on Matrigel was performed using HUVECs grown
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for 18 h in a humidified 37◦C, 5% CO2 incubator. Separate
dishes were exposed or not to hrDkk-3 (10 ng/ml) either
in the presence or in the absence of the VEGFR2 inhibitor
ZM 3238881. The same experimental design was applied to
ALK1 gene silenced cells. At the end of exposure, plates were
photographed with a microscope (Zeiss, Jena, Germany) fitted
with a digital camera. Quantification was performed by using the
Angiogenesis Analyzer for ImageJ software in randomly chosen
10X microscopic fields.
Statistical Analyses
Statistical analyses were performed using unpaired t test
(Figures 4G, 5A) and One Way ANOVA followed by
Bonferroni’s LSD test (Figures 1A, 5B) or Fisher’s LSD test
(Figures 1D,F, 2C,D, 3C, 4B,D,F, 5C,D, 6B) or Dunnett’s LSD
test (Figure 2A) or Tukey’s LSD test (Figure 5E) and Two Way
ANOVA followed by Fisher (Figure 3A).
RESULTS
VEGF Was Upregulated in HUVECs
following Incubation with hrDkk-3
To evaluate whether Dkk-3 modulates VEGF expression in
the endothelium, we performed in vitro experiments using
culturedHUVECs. Treatment with hrDkk-3 resulted in amarked
upregulation of mRNA VEGF level (Figures 1A,B).
Immunocytochemical and western blot analyses showed
a significant upregulation of the VEGF intracellular protein
level following incubation with hrDkk-3 at both 6 and 12 h
(Figures 1C–F). Moreover, a large increase in the extracellular
VEGF level was observed following incubation with hrDkk-3 (1
or 10 ng/ml) (Figure 2A). This increase was associated to an
enhanced VEGFR2 phosphorylation (Figures 2B,C).
Dkk-3-Induced Angiogenesis Is Mediated
by VEGF
The proangiogenic activity of hrDkk-3 was demonstrated by a
significant increase in the time course of endothelial cell tubes
formation at both 6 and 18 h (Figure 3A).
To examine whether VEGF was involved in the angiogenic
effect of Dkk-3, we repeated the endothelial cell tubes formation
assay in the presence of the pharmacological blockade of VEGR2.
In fact, ZM 323881, which was inactive on its own, abrogated the
enhancing effect of Dkk-3 on angiogenesis (Figures 3B,C).
Dkk-3 Enhanced Smad1,5,8
Phosphorylation
We studied the mechanism by which hrDkk-3 enhanced VEGF
expression and promoted in vitro angiogenesis focusing on
TGF-β receptor signaling. Moving from the evidence that
TGF-β stimulates endothelial cell proliferation via type-1 TGF-
β/ALK1 receptor activation and the ensuing phosphorylation
of Smad1,5,8 transcription factors (Lebrin et al., 2005), we
examined whether this signaling mechanism could be involved
in the molecular actions of Dkk-3 in HUVECs. The western
blot analysis showed a significant increase in phosphorylated-
Smad1,5,8 levels in HUVECs treated with hrDkk-3 at all
FIGURE 1 | Dkk-3 upregulates the intracellular VEGF expression level.
RTPCR (A,B), immunocytochemical (C,D), western blot analysis (E,F) of
VEGF in HUVECs incubated with hrDkk-3 (1 ng/ml or 10 ng/ml) for either 6 or
12 h. Values are means ± SEM. *p < 0.05 vs. baseline condition; **p < 0.001
vs. baseline condition.
incubation times (Figure 4). These data suggest that Dkk-3 is able
to activate, either directly or indirectly, ALK1 receptor.
Finally, we performed a ChIP analysis in order to evaluate
whether the exposure to Dkk-3 may lead to an increased
Smad4 binding to the VEGF promoter. Our results showed an
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FIGURE 2 | Dkk-3 upregulates the extracellular VEGF expression level
and increases the VEGFR2 activation. (A) ELISA of VEGF in the medium
cell culture after incubation with hrDkk-3 (1 ng/ml or 10 ng/ml) for 6 h. Values
are means ± SEM. *p < 0.05 vs. baseline condition. (B) Western blot analysis
of P-VEGFR2 in cells incubated with hrDkk-3 (1 ng/ml or 10 ng/ml) for either 6
or 12 h. (C,D) Corresponding densitometric analysis. Values are means ±
SEM. *p < 0.05 vs. baseline condition, **p < 0.001 vs. baseline condition.
increased binding of Smad4 to the VEGF promoter in response
to incubation with Dkk-3 (Figure 4G). Therefore, the molecular
mechanism of Dkk-3-mediated VEGF upregulation appears to be
a transcriptional activation that occurs through the Smad1,5,8
phosphorylation and the ensuing recruitment of the Smad4
factor (Figure 4H).
ALK1 Gene Silencing Inhibited Smad1,5,8
Phosphorylation, the Enhanced VEGF
Expression and Endothelial Cell Tubes
Formation Induced by Dkk-3
To examine whether ALK1 activation was causally related
to the effect of Dkk-3 on Smad1,5,8 phosphorylation,
VEGF expression and angiogenesis, we silenced ALK1
gene with a specific siRNA. The efficiency of ALK1 gene
silencing was verified by RTPCR for 48 h after transfection
(Figure 5A).
FIGURE 3 | Angiogenic-like activity of Dkk-3 is mediated by VEGF. (A)
Quantification of endothelial cell tubes on Matrigel at different times of
incubation with hrDkk-3. Values are means ± SEM. *p < 0.05 vs. baseline
condition. (B,C) Endothelial cell tubes formation following 18 h of incubation
with hrDkk-3 either in the presence or in the absence of the selective VEGFR2
receptor antagonist ZM 323881. In (B) representative images of endothelial
cell tube are shown following 18 h of incubation with hrDkk-3 and/or ZM
323881. In (C) the corresponding quantification of endothelial cell tubes are
shown. Values are means ± SEM. *p < 0.05 vs. baseline condition; ##p <
0.001 vs. hrDkk-3.
The ALK1 gene silencing prevented the increase in
phosphorylated-Smad1,5,8 levels induced by hrDkk-3
(Figure 5B). Moreover, ALK1 silencing abrogated the VEGF
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FIGURE 4 | Dkk-3 enhances the expression of phospho-Smad1/5/8.
(A–F) Western blots and the corresponding densitometric analysis of
phospho-Smad1/5/8 in cells incubated with hrDkk-3 for different times (30, 60,
and 90 min). HUVECs incubated with TGF-β1 (25 ng/ml) were used as positive
controls. Values are means ± SEM. **p < 0.001 vs. baseline condition. (G)
ChIP assay showing the increased binding of Smad4 to the VEGF promoter in
response to the incubation with hrDkk-3 (10 ng/ml, 60 min). Values are means
± SD and are expressed as percentage of inputs. *p < 0.05 vs. baseline
condition. (H) Schematic representation of the signaling events occurring in
cells in response to Dkk-3 exposure and leading to VEGF transcriptional
upregulation through a recruitment of the Smad1,5,8 and Smad4.
upregulation and the angiogenesis process induced by hrDkk-3
(Figures 5C–E).
These data demonstrate that ALK1 activation lies upstream in
the chain of events leading to VEGF induction and angiogenesis
in response to Dkk-3.
ALK1 Pharmacological Blockade Inhibited
the VEGF Upregulation Induced by Dkk-3
In order to confirm the involvement of the ALK1 receptor
in hrDkk-3 mediated VEGF upregulation, we examined the
effect of ALK1 pharmacological blockade by using the selective
FIGURE 5 | ALK1 receptor gene silencing by siRNA abrogates
Smad1/5/8 phosphorylation, VEGF upregulation and angiogenesis
induced by Dkk-3. (A) RTPCR analysis of ALK1 mRNA level in both control
and ALK1 silenced cells. **p < 0.001 vs. control-siRNA treated cells. (B)
Western blot analysis of phospho-Smad1,5,8 expression in both control and
ALK1 silenced cells exposed to hrDkk-3 (10 ng/ml, 60 min). HUVECs
incubated with TGF-β1 were used as positive controls. Values are means ±
SEM. **p < 0.001 vs. baseline conditions, ##p < 0.001 vs. hrDkk-
3. Immunocytochemical (C) and western blot analysis (D) of VEGF expression in
(Continued)
Frontiers in Pharmacology | www.frontiersin.org 6 March 2017 | Volume 8 | Article 111
Busceti et al. Dkk3/VEFG/TGF-β Interactions
FIGURE 5 | Continued
both control and ALK1 silenced cells exposed to hrDkk-3 (10 ng/ml, 12 h).
Values are means ± SEM. **p < 0.001 vs. baseline conditions, #p < 0.05 vs.
hrDkk-3, ##p < 0.001 vs. hrDkk-3. (E) Endothelial cell tube formation of both
control and ALK1 silenced cells treated with hrDkk-3 (10 ng/ml, 18 h). Values
are means ± SEM. *p < 0.05 vs. baseline conditions, #p < 0.05 vs. hrDkk-3.
FIGURE 6 | ALK1 receptor pharmacological blockade abrogates VEGF
upregulation induced by Dkk-3 in HUVECs. (A) Western blot analysis of
VEGF expression in HUVECs exposed to hrDkk-3 (10 ng/ml, 12 h) either in the
presence or in the absence of the selective inhibitor ML347 (0.5 M or 3 µM).
(B) Corresponding densitometric analysis. Values are means ± SEM. **p <
0.001 vs. baseline conditions, ##p < 0.001 vs. hrDkk-3.
ALK1 inhibitor ML347. Our results showed that ML347
exposure abrogated the VEGF upregulation induced by hrDkk-3
(Figure 6).
TGF-β Neutralization Does Not Inhibit
Smad1,5,8 Phosphorylation and the VEGF
Upregulation Induced by Dkk-3
We used a specific TGF-β neutralizing antibody to evaluate
whether the ability of Dkk-3 to activate the ALK1 signaling and
stimulate VEGF upregulation occurs through a cross talk with
TGF-β. Our results showed that the TGF-β neutralization does
not interfere with Dkk-3-mediated Smad1,5,8 phosphorylation
(Figures 7A,B) or with VEGF upregulation (Figures 7C,D).
These data suggest that the molecular axis Dkk-3/ALK1/VEGF
does not require a cross talk between Dkk-3 and TGF-β.
DISCUSSION
Dkk-3 was initially identified as a tumor suppressor (Tsuji
et al., 2000, 2001), and was also shown to be involved
FIGURE 7 | TGF-β neutralizing antibody does not inhibit Smad1,5,8
phosphorylation and the VEGF upregulation induced by Dkk-3. (A)
Western blot analysis of phosphoSmad1,5,8 in cells exposed for 60 min to
hrDkk-3 either in the presence or in the absence of neutralizing TGF-β
antibody. (B) Corresponding densitometric analysis. Values are means ± SD.
(C) Western blot analysis of VEGF in cells exposed for 12 h to hrDkk-3 either in
the presence or in the absence of neutralizing TGF-β antibody. (D)
Corresponding densitometric analysis. Values are means ± SD.
in epithelial cell senescence (Untergasser et al., 2002), and
acinar cell differentiation and morphogenesis (Kawano et al.,
2006). More recent studies have demonstrated that Dkk-3 acts
as a differentiation factor involved in remodeling of tumor
vasculature (Untergasser et al., 2008). In particular, Dkk-3 is
strongly expressed in tumor endothelial cells, and appears to be
involved in capillary formation and angiogenesis (Untergasser
et al., 2008).
Thus, Dkk-3 may contribute to maintain blood vessel wall
structure both under physiological conditions and in response
to pathological stimuli through its ability to act as an angiogenic
factor.
The angiogenic activity of Dkk-3 was demonstrated in cultures
of endothelial colony-forming cultures as shown by the altered
endothelial cell tubes formation on Matrigel after Dkk-3 gene
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downregulation or adenoviral overexpression (Untergasser et al.,
2008).
The molecular mechanisms underlying the angiogenic action
of Dkk-3 at the endothelial level have not been yet identified.
Herein, we have shown for the first time that Dkk-3 increases
the intracellular VEGF expression and the extracellular VEGF
release with an ensuing activation of VEGFR2 receptor in
endothelial cells. Moreover, we demonstrated that activation of
VEGFR2 was ultimately responsible for the in vitro angiogenic-
like effects of Dkk-3.
VEGF plays a fundamental role in mechanisms of
vasculogenesis and angiogenesis in both physiological and
pathological conditions (Ferrara et al., 2003; Ferrara, 2004).
VEGF acts by inducing endothelial cell proliferation, survival
and migration resulting into the formation of capillary-like
tubules (Darland et al., 2003; Gerhardt et al., 2003). Genetic
deletion of a single VEGF allele leads to embryonic death
with severe vascular defects (Carmeliet et al., 1996; Ferrara
et al., 1996). In addition, VEGF has been implicated in the
physiological control of vasculature function as well as in
vascular dysfunction associated with neural grafting, tumor cell
implantation, tumor development, transient forebrain ischemia,
and hypertension (Krum and Rosenstein, 1998; Nishikawa
et al., 1998; Lee et al., 1999; Chow et al., 2001; Ferrara et al.,
2004; Hurwitz et al., 2004; Hicklin and Ellis, 2005; Bhargava,
2009). Therefore, the functional link between Dkk-3 and VEGF
currently identified in endothelial cells raises the possibility that
Dkk-3 represents an important molecular player involved in
vascular health and disease through VEGF modulation.
We performed experiments to characterize the molecular
mechanism underlying the VEGF upregulation and the related
angiogenic activity dependent on Dkk-3 in HUVECs. The main
difficulty was related to the lack of information of a putative
Dkk-3 receptor. Unlike the other Dkk members, Dkk3 does not
interact with the Wnt signaling (Krupnik et al., 1999; Wu et al.,
2000; Mao B. et al., 2001; Mao J. et al., 2001) and it does not show
affinity to the Wnt co-receptors LRP5/6 and Kremen (Mao B.
et al., 2001; Mao J. et al., 2001; Mao et al., 2002; Diep et al., 2004).
Remarkably, Dkk-3 is able to up-regulate ATF3 and enhance
Smad3 phosphorylation in tumor cell lines (Kashiwakura et al.,
2008). Moreover, depletion of Dkk-3 in Xenopus embryos by
antisense oligonucleotides strongly reduced levels of Smad4
protein (Pinho and Niehrs, 2007). Both ATF3 and Smads are
components of the intracellular signaling pathway activated by
TGF-β.
We therefore focused on TGF-β signaling as a potential
mediator of Dkk-3 actions in endothelial cells.
TGF-β has an established role in vascular homeostasis
(Ten Dijke and Arthur, 2007) and angiogenesis (Pepper, 1997;
Goumans et al., 2003). In fact, mice lacking TGF-β1 die in
utero owing to vascular defects (Dickson et al., 1995). TGF-β
activates type-I and type-II transmembrane serine/threonine-
kinase receptors. Binding of TGF-β to the type-II receptor leads
to recruitment and phosphorylation of type-I receptor ALK1
and ALK5. Following activation of type I receptors, the signal is
transduced from the membrane to the nucleus via intracellular
effectors, called Smads (Derynck and Zhang, 2003; Ten Dijke
and Hill, 2004). Activated ALK1 phosphorylates the downstream
effectors, Smad1, Smad5, and Smad8, whereas activated ALK5
phosphorylates Smad2 and Smad3 (Goumans et al., 2002).
TGF-β modulates endothelial cell proliferation and migration
via a fine balance between ALK5 and ALK1 signaling, with
ALK1 enhancing endothelial cell migration and proliferation,
and ALK5 doing the opposite (Goumans et al., 2002; Lebrin et al.,
2005). TGF-β can also modulate angiogenesis by regulating the
expression of VEGF in vascular endothelial cells (Seghezzi et al.,
1998; Ferrari et al., 2006).
Here, we have shown that Dkk-3 was able to activate
ALK1 receptor in endothelial cells, as suggested by the
increase in Smad1/5/8 phosphorylation, and to induce the
Smad4 recruitment to the VEGF promoter. The ALK1 receptor
activation laid upstream in the chain of events induced by Dkk-3,
since both ALK1 silencing and the pharmacological blockade of
ALK1 receptor abrogated the Dkk-3-induced VEGF expression
and angiogenesis. These data demonstrate that the type-I TGF-
β/ALK1 receptor plays a key role inmediating the action of Dkk-3
in endothelial cells.
Moreover, experiments of TGF-β neutralization allowed us
to demonstrate that the Dkk-3 mediated activation of ALK1
receptor does not require a cross talk between Dkk-3 and TGF-β.
We cannot exclude the existence of a molecular partner of Dkk-3
favoring its action on ALK1 receptor. On the other hand, the
presence of TGF-β is not required for ALK1 activation and VEGF
upregulation mediated by Dkk-3 in endothelial cells. Therefore,
whether Dkk-3 is a direct activator of TGF-β receptor or it acts on
a different membrane receptor that trans-activates ALK1 remains
to be determined.
Taken together our data demonstrate that Dkk-3 acts on
endothelial cells by activating the ALK1 receptor with ensuing
Smad1,5,8 phosphorylation, Smad4 recruitment to the VEGF
promoter, transcriptional upregulation of VEGF which, in turn,
mediates the angiogenic activity through the VEGFR2 activation.
The functional link between Dkk-3 and ALK1 in endothelial
cells suggests a role for Dkk-3 in vascular pathology. Smad1 and
Smad5 are phosphorylated in endothelial cells in response to
oscillatory shear stress resulting into cell cycle progression (Zhou
et al., 2012). Thus, Dkk-3 might promote vascular remodeling
under pathological conditions by enhancing Smad1, Smad5 and
Smad8 phosphorylation. According to this hypothesis, mutations
in the ALK1 receptor gene have been associated with vascular
disorders, such as Haemorrhagic Telengiectasia (Johnson et al.,
1996) and pulmonary arterial hypertension (Machado et al., 2009;
Jerkic et al., 2011; Gore et al., 2014). In addition, heterozygous
disruption of ALK1 receptor is associated with increased arterial
blood pressure in mice (González-Núñez et al., 2015).
CONCLUSIONS
We have shown for the first time the following cascade of events
in endothelial cells:
(1) Dkk-3 activates type-I TGF-β receptor, ALK1, inducing
phosphorylation of Smad1/5/8 and the Smad4 recruitment
to the VEGF promoter;
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(2) Dkk-3-mediated ALK1 activation leads to a VEGF
transcriptional upregulation;
(3) Activation of VEGF receptor mediates the angiogenic
activity of Dkk-3.
The functional characterization of Dkk-3/ALK1/VEGF as a
new molecular axis in the endothelial vascular compartment
highlights a novel role of Dkk-3, raising the possibility that the
chain of events triggered by Dkk-3 might represent a novel target
for the treatment of vascular diseases.
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